Chr. Hansen’s Latest Probiotics Research, as Presented at IPC 2016
27 Jun 2016 --- At the International Scientific Conference on Probiotics and Prebiotics last week (21-23 June) in Budapest, Hungary, Senior Principal Scientist Thomas D. Leser at Human Health Discovery presented a poster on some of Chr. Hansen’s latest probiotics research.
Entitled “Probiotic Strains of Bifidobacterium adolescentis”, the poster by Leser et al. 2016 concludes that in vitro data indicate that B. adolescentis BIF038 could be a new probiotic candidate that may improve the intestinal barrier and induce a regulatory mucosal immune response.
The DSS (dextran sodium sulfate) colitis model showed that BIF038 prevented and/or attenuated inflammation and tissue damage in the gastrointestinal tract and ameliorated DSS-induced body weight loss, thus confirming the beneficial effects of this strain demonstrated in vitro.
Continuous screening
The study is part of Chr. Hansen’s continuous screening efforts to detect probiotic strains with promising characteristics to be used in commercial products at a later stage. “We have one of the largest culture banks in the world and put our state-of-the art technology to use when we screen for the best probiotic candidates. I look forward to discussing the results with fellow researchers in the probiotics field,” said Thomas D. Leser.
The study is part of Chr. Hansen’s continuous screening efforts to detect probiotic strains with promising characteristics to be used in commercial products at a later stage. “We have one of the largest culture banks in the world and put our state-of-the art technology to use when we screen for the best probiotic candidates. I look forward to discussing the results with fellow researchers in the probiotics field,” said Thomas D. Leser.
All content and features on this website are copyrighted with all rights reserved. The full details can be found in our privacy statement
